This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets.
Business Questions:
- How do the KOLs perceive the Phase II combination results for BMS’ Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer?
- Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward?
- What are experts’ thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?
- Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?
- If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor?
- Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC?
- Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?
- How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent?
- If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC?
- What are KOLs’ opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed?
